Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Hematology Hematology for January/February 2021 Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A, More must reads Hematology for November/December 2020 DOACs look safe in elective endoscopic procedures, Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant, Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction, Mouth splints decrease risk of post–dental extraction bleeding in hemophilia, More must readsHematology for September/October 2020 Socioeconomic factors affect survival of multiple myeloma patients, Older adults with multiple myeloma face heavy burden of care, INR fails to predict bleeding in patients with cirrhosis, Lusutrombopag found safe, effective for severe thrombocytopenia in patients with hepatocellular carcinoma, Low VWF levels or blood group O not linked to intracerebral hemorrhage risk, More must readsHematology for July/August 2020 Age, other risk factors predict length of MM survival, Polygenic risk score may predict VTE in adolescents, but not adults, with ALL, BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patients, Large cohort study: Bevacizumab safe, effective for severe HHT bleeds, Transitioning regimen may prolong proteasome inhibitor–based therapy for MM, More must readsHematology for May/June 2020 Combo drug improves survival in older patients with high-risk/secondary AML, Venetoclax plus LDAC tops LDAC alone in AML, Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML, Subcutaneous hep A vaccination as effective as intramuscular for bleeding disorder patients, Tandem transplantation, long-term maintenance may extend MM remission, More must readsPages1 2 3 4 last »
